IN2012DN03128A - - Google Patents

Download PDF

Info

Publication number: IN2012DN03128A
Authority: IN; India
Prior art keywords: compositions; eye; active ingredient; treatment; group
Prior art date: 2009-12-14

Application number

Other languages

English (en)

Inventor

Bastian Theisinger

Sonja Theisinger

Bernhard Gunther

Original Assignee

Novaliq Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-14

Filing date

2010-12-13

Publication date

2015-09-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41731659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03128(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-12-13 Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh

2015-09-18 Publication of IN2012DN03128A publication Critical patent/IN2012DN03128A/en

Links

239000000203 mixture Substances 0.000 abstract 2
208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
206010013774 Dry eye Diseases 0.000 abstract 1
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
150000001335 aliphatic alkanes Chemical class 0.000 abstract 1
229960003444 immunosuppressant agent Drugs 0.000 abstract 1
239000003018 immunosuppressive agent Substances 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
239000003120 macrolide antibiotic agent Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IN3128DEN2012 2009-12-14 2010-12-13 IN2012DN03128A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP09015423A EP2335735A1 (fr)	2009-12-14	2009-12-14	Composition pharmaceutique pour le traitement de la kératoconjonctivite sèche
PCT/EP2010/069495 WO2011073134A1 (fr)	2009-12-14	2010-12-13	Composition pharmaceutique pour le traitement du syndrome de l'oeil sec

Publications (1)

Publication Number	Publication Date
IN2012DN03128A true IN2012DN03128A (fr)	2015-09-18

Family

ID=41731659

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN3128DEN2012 IN2012DN03128A (fr)	2009-12-14	2010-12-13

Country Status (15)

Country	Link
US (1)	US8614178B2 (fr)
EP (2)	EP2335735A1 (fr)
JP (5)	JP5663595B2 (fr)
KR (2)	KR101652714B1 (fr)
CN (1)	CN102652022B (fr)
AU (1)	AU2010333039B2 (fr)
BR (3)	BR122017018955B1 (fr)
CA (2)	CA2941956C (fr)
DK (1)	DK2512515T3 (fr)
ES (1)	ES2449308T3 (fr)
IN (1)	IN2012DN03128A (fr)
MX (1)	MX2012006720A (fr)
PL (1)	PL2512515T3 (fr)
PT (1)	PT2512515E (fr)
WO (1)	WO2011073134A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2437684B1 (fr)	2009-06-03	2022-06-15	ForSight Vision5, Inc.	Distribution de médicament de segment antérieur
PL2547323T3 (pl)	2010-03-17	2016-07-29	Novaliq Gmbh	Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
EP2444063A1 (fr)	2010-10-20	2012-04-25	Novaliq GmbH	Compositions pharmaceutiques liquides pour l'administration de principes actifs
EP2462921A1 (fr)	2010-11-11	2012-06-13	Novaliq GmbH	Compositions pharmaceutiques liquides pour le traitement d'une maladie de la chambre postérieure de l'oeil
JP6023181B2 (ja)	2011-05-25	2016-11-09	ノバリックゲーエムベーハー	爪に投与するための医薬組成物
DK2714010T3 (en)	2011-05-25	2017-06-12	Novaliq Gmbh	TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES
KR101989648B1 (ko) *	2012-01-23	2019-06-14	노바리크 게엠베하	부분불소화 알칸에 기초한 안정화된 단백질 조성물
CN113679699B (zh)	2012-09-12	2022-10-28	诺瓦利克有限责任公司	包含半氟化烷烃的混合物的组合物
AU2013314303B2 (en) *	2012-09-12	2018-01-18	Novaliq Gmbh	Semifluorinated alkane compositions
DK2708228T3 (en)	2012-09-12	2018-08-20	Novaliq Gmbh	COMPOSITION FOR EYE RINSE
EP2730291A1 (fr) *	2012-11-09	2014-05-14	Fluoron Gmbh	Composition de tamponnade interne
AU2014209141B2 (en)	2013-01-24	2018-05-10	Palvella Therapeutics, Inc.	Compositions for transdermal delivery of mTOR inhibitors
JP6304475B2 (ja) *	2013-01-31	2018-04-04	ロート製薬株式会社	点眼剤
CN105073112B (zh) *	2013-03-13	2017-12-29	参天制药株式会社	睑板腺功能障碍的治疗剂
PT3024484T (pt)	2013-07-23	2018-10-24	Novaliq Gmbh	Composições de anticorpo estabilizadas
EP3057514A4 (fr) *	2013-10-15	2017-08-02	Forsight Vision5, Inc.	Préparations et méthodes permettant d'augmenter ou de réduire le mucus
US11324800B2 (en)	2015-01-15	2022-05-10	Wellspring Ophthalmics, Inc.	Aqueous suspensions of cyclosporin
US20200237859A1 (en)	2019-01-25	2020-07-30	Newport Research, Inc.	Aqueous suspensions of cyclosporin
US20160296532A1 (en)	2015-04-13	2016-10-13	Forsight Vision5, Inc.	Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11013403B2 (en) *	2015-09-29	2021-05-25	The Regents Of The University Of California	Methods of diagnosing diseases of mucosal surfaces
US11154513B2 (en) *	2015-09-30	2021-10-26	Novaliq Gmbh	Semifluorinated compounds
CN110403923B (zh) *	2015-09-30	2021-09-21	诺瓦利克有限责任公司	半氟化化合物和其组合物
PT3442480T (pt)	2016-06-23	2019-12-23	Novaliq Gmbh	Método de administração tópica
CA3036297C (fr)	2016-09-22	2023-09-05	Novaliq Gmbh	Compositions pharmaceutiques destinees a etre utilisees dans la therapie de la blepharite
WO2018055101A1 (fr)	2016-09-23	2018-03-29	Novaliq Gmbh	Compositions ophtalmiques contenant de la cyclosporine
AU2017333420A1 (en) *	2016-09-28	2019-04-04	Novaliq Gmbh	Compositions comprising a cannabinoid receptor binding ligand
BR112019012568A2 (pt) *	2016-12-22	2019-11-26	Novaliq Gmbh	composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias
EP4374851B1 (fr) *	2016-12-23	2026-04-15	Novaliq GmbH	Composition ophtalmique pour le traitement d'une maladie de l' oeil sec
EP3565520B1 (fr)	2017-01-06	2026-02-25	Palvella Therapeutics, Inc.	Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
CA3058097C (fr)	2017-04-21	2024-01-02	Novaliq Gmbh	Compositions d'iode
WO2018202835A1 (fr)	2017-05-05	2018-11-08	Novaliq Gmbh	Procédé de production d'alcanes semi-fluorés
US11278503B2 (en)	2017-05-12	2022-03-22	Novaliq Gmbh	Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es)	2017-09-27	2020-07-29	Novaliq Gmbh	Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
WO2019068763A1 (fr)	2017-10-04	2019-04-11	Novaliq Gmbh	Compositions ophtalmiques comprenant du f6h8
KR20200128407A (ko)	2018-03-02	2020-11-12	노바리크 게엠베하	네비볼롤을 포함하는 약제학적 조성물
SG11202007860XA (en)	2018-03-28	2020-09-29	Novaliq Gmbh	Pharmaceutical composition comprising timolol
CN112153970A (zh)	2018-04-27	2020-12-29	诺瓦利克有限责任公司	用于治疗青光眼的包含他氟前列素的眼用组合物
US11000513B2 (en)	2018-07-02	2021-05-11	Palvella Therapeutics, Inc.	Anhydrous compositions of mTOR inhibitors and methods of use
WO2020058504A1 (fr) *	2018-09-22	2020-03-26	Novaliq Gmbh	Compositions ophtalmiques pour le traitement de lésions de surface oculaire et de symptômes de sécheresse
EP3856124A1 (fr)	2018-09-27	2021-08-04	Novaliq GmbH	Réparation de la barrière lipidique
SG11202102820VA (en) *	2018-10-12	2021-04-29	Novaliq Gmbh	Ophthalmic composition for treatment of dry eye disease
WO2020152046A1 (fr) *	2019-01-21	2020-07-30	Novaliq Gmbh	Composition pharmaceutique pour le traitement de la néovascularisation oculaire
EP3923907B1 (fr)	2019-02-13	2024-09-25	Novaliq GmbH	Compositions et procédés pour le traitement de la néovascularisation oculaire
WO2020239646A1 (fr)	2019-05-24	2020-12-03	Novaliq Gmbh	Composition ophtalmique pour le traitement d'une allergie oculaire
KR20220058577A (ko)	2019-09-06	2022-05-09	노바리크 게엠베하	포도막염 치료를 위한 안과용 조성물
WO2021048803A1 (fr)	2019-09-13	2021-03-18	Minas Coroneo	Distributeur de gouttes oculaires
WO2021191273A1 (fr)	2020-03-24	2021-09-30	Hovione Scientia Limited	Compositions destinées à être utilisées dans le traitement d'un dysfonctionnement de la glande de meibomius
US11191751B1 (en) *	2020-10-08	2021-12-07	Ads Therapeutics Llc	Topical ophthalmological atropine free base compositions
IL322635A (en) *	2023-02-13	2025-10-01	Novaliq Gmbh	Ophthalmic preparation for eye surgery in patients with ocular surface disease
AU2023270196B2 (en) *	2023-11-20	2025-06-26	Dyer, Gordon Wayne DR	Method of Arthropod Egress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR920003601B1 (ko)	1987-09-03	1992-05-04	유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드	점안 싸이클로스포린(cyclosporin)의 조성물
US4839342A (en)	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin
US5874481A (en) *	1995-06-07	1999-02-23	Alliance Pharmaceutical Corp.	Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de)	1995-09-29	1999-09-23	H Meinert	Verwendung fluorierter Alkane
DE19861012A1 (de) *	1998-03-18	1999-09-30	Pharm Pur Gmbh	Behandlungsmittel für die Ophthalmologie
WO2000066122A1 (fr) *	1999-04-30	2000-11-09	Sucampo Ag	Utilisation de composes macrolides pour le traitement des yeux secs
DE19938668B4 (de) *	1999-08-14	2006-01-26	Bausch & Lomb Inc.	Tränenersatzmittel
US20030018044A1 (en) *	2000-02-18	2003-01-23	Peyman Gholam A.	Treatment of ocular disease
WO2005099718A1 (fr) *	2004-04-19	2005-10-27	Centre National De La Recherche Scientifique (C.N.R.S.)	Complements de surfactant pulmonaire
MXPA06014425A (es) *	2004-06-08	2007-05-23	Ocularis Pharma Inc	Composiciones oftalmicas hidrofobas y metodo de uso.
DE102007055046A1 (de) *	2007-11-19	2009-05-28	Fluoron Gmbh	Infusionslösung
ES2377152T3 (es)	2008-04-18	2012-03-22	Novaliq Gmbh	Uso inhalativo e instilativo de alcanos semifluorados como vehículos de principios activos en la región intrapulmonar

2009
- 2009-12-14 EP EP09015423A patent/EP2335735A1/fr not_active Withdrawn
2010
- 2010-12-13 KR KR1020127018066A patent/KR101652714B1/ko active Active
- 2010-12-13 BR BR122017018955-7A patent/BR122017018955B1/pt active IP Right Grant
- 2010-12-13 PT PT107907750T patent/PT2512515E/pt unknown
- 2010-12-13 CN CN201080055507.7A patent/CN102652022B/zh active Active
- 2010-12-13 WO PCT/EP2010/069495 patent/WO2011073134A1/fr not_active Ceased
- 2010-12-13 US US13/513,886 patent/US8614178B2/en active Active
- 2010-12-13 AU AU2010333039A patent/AU2010333039B2/en active Active
- 2010-12-13 CA CA2941956A patent/CA2941956C/fr active Active
- 2010-12-13 DK DK10790775.0T patent/DK2512515T3/en active
- 2010-12-13 JP JP2012542577A patent/JP5663595B2/ja active Active
- 2010-12-13 IN IN3128DEN2012 patent/IN2012DN03128A/en unknown
- 2010-12-13 EP EP10790775.0A patent/EP2512515B1/fr active Active
- 2010-12-13 PL PL10790775T patent/PL2512515T3/pl unknown
- 2010-12-13 KR KR1020167023214A patent/KR101722039B1/ko active Active
- 2010-12-13 BR BR122020020872-4A patent/BR122020020872B1/pt active IP Right Grant
- 2010-12-13 ES ES10790775.0T patent/ES2449308T3/es active Active
- 2010-12-13 MX MX2012006720A patent/MX2012006720A/es active IP Right Grant
- 2010-12-13 BR BR112012014190A patent/BR112012014190B8/pt active IP Right Grant
- 2010-12-13 CA CA2776860A patent/CA2776860C/fr active Active
2014
- 2014-10-01 JP JP2014203406A patent/JP6096731B2/ja active Active
2016
- 2016-12-22 JP JP2016248533A patent/JP6397472B2/ja active Active
2018
- 2018-08-31 JP JP2018163569A patent/JP2019006803A/ja active Pending
- 2018-12-28 JP JP2018248700A patent/JP6731039B2/ja active Active

Also Published As

Publication number	Publication date
AU2010333039B2 (en)	2014-08-28
BR112012014190B1 (pt)	2021-03-02
AU2010333039A1 (en)	2012-07-12
EP2512515A1 (fr)	2012-10-24
JP2019070003A (ja)	2019-05-09
US20120244177A1 (en)	2012-09-27
CA2776860A1 (fr)	2011-06-23
KR20120115977A (ko)	2012-10-19
JP2019006803A (ja)	2019-01-17
EP2512515B1 (fr)	2013-12-25
JP6096731B2 (ja)	2017-03-15
JP5663595B2 (ja)	2015-02-04
KR101722039B1 (ko)	2017-03-31
KR20160105533A (ko)	2016-09-06
KR101652714B1 (ko)	2016-09-01
CA2941956C (fr)	2018-09-04
BR112012014190B8 (pt)	2021-05-25
CA2941956A1 (fr)	2011-06-23
CN102652022B (zh)	2014-12-17
DK2512515T3 (en)	2014-03-10
ES2449308T3 (es)	2014-03-19
CA2776860C (fr)	2016-10-25
JP2017078086A (ja)	2017-04-27
HK1172269A1 (en)	2013-04-19
JP2015028064A (ja)	2015-02-12
JP2013513586A (ja)	2013-04-22
CN102652022A (zh)	2012-08-29
JP6731039B2 (ja)	2020-07-29
PL2512515T3 (pl)	2014-05-30
BR122020020872B1 (pt)	2021-09-08
PT2512515E (pt)	2014-03-04
BR122017018955B1 (pt)	2022-03-08
BR112012014190A2 (pt)	2016-05-31
JP6397472B2 (ja)	2018-09-26
US8614178B2 (en)	2013-12-24
EP2335735A1 (fr)	2011-06-22
MX2012006720A (es)	2012-07-30
WO2011073134A1 (fr)	2011-06-23

Publication	Publication Date	Title
IN2012DN03128A (fr)	2015-09-18
WO2015106128A3 (fr)	2015-10-08	Agents d'arni modifiés
NZ708593A (en)	2018-01-26	Novel pyrazole derivative
MY175800A (en)	2020-07-09	Combination treatment of cancer
EP4342540A3 (fr)	2024-05-29	Dérivés hétérocyclyle substitués en tant qu'inhibiteurs de cdk
EP4292662A3 (fr)	2024-02-21	Inhibiteurs d'indoles mcl-1 substitués
WO2015070224A3 (fr)	2015-08-13	Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
WO2011113802A3 (fr)	2012-08-02	Composés d'imidazopyridine, compositions et procédés d'utilisation
EA033343B1 (ru)	2019-09-30	Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
MX2016011468A (es)	2017-01-23	Inhibidores de calicreína plasmática humana.
MX2013012776A (es)	2013-11-21	Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
BR112017003054A2 (pt)	2017-11-21	compostos de aminopirimidinila como inibidores de jak
BR112014000792A2 (pt)	2017-10-31	compostos de piperidinila para uso como inibidores da tanquirase
EP4342537A3 (fr)	2024-07-03	Compositions d'alcane semifluoré
CL2012001714A1 (es)	2013-04-12	Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras.
WO2012027065A3 (fr)	2012-05-10	Polythérapie pour traiter des maladies
DOP2019000275A (es)	2019-11-15	Nuevos derivados de pirazol bicíclicos
EP4414376A3 (fr)	2024-11-06	Nouveau depsipeptide et ses utilisations
EP4403552A3 (fr)	2024-10-16	Inhibiteurs de hsp90 c-terminaux
WO2014028931A3 (fr)	2014-10-09	Composés et procédés de traitement d'infections microbiennes gastro-intestinales de mammifère
EP3216798A3 (fr)	2017-10-25	Composés kétolides
MX341220B (es)	2016-08-10	Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas.
EP4299126A3 (fr)	2024-04-03	Modulateurs allostériques positifs au gaba restreints au système nerveux périphérique pour le traitement du syndrome du côlon irritable et autres affections du système nerveux périphérique
PH12013500644A1 (en)	2013-05-20	Co-crystals and salts of ccr3-inhibitors
CL2012003521A1 (es)	2013-02-15	Derivado piperidino (r)-n-((r)-1-((3s-4s)-4-(4-clorofenil)-3,4-dihidroxi-3-metilpiperidin-1-il)-3-metil-1-oxobutan-2-il)-3,3-difluorociclopentanocarboxamida, modulador receptor quimiocinas; composicion farmaceutica; y uso del compuesto y su composicion en enfermedades inflamatorias y autoinmunitarias, entre otras.